Plain-English translation of NCT06237920 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , an immunotherapy drug that helps your immune system fight cancer, works better when combined with another immunotherapy drug called before bladder removal surgery. The study will compare two groups: one receiving alone and another receiving plus . Both groups will receive two doses of their assigned treatment, spaced about four weeks apart, followed by surgery to remove the bladder.
Currently, chemotherapy is the standard treatment before bladder cancer surgery, but some patients cannot tolerate it or prefer not to receive it. This study is exploring whether newer immunotherapy medications can be an effective alternative for these patients.
You likely qualify if…
You likely don't qualify if…
You will receive two doses of your assigned treatment intravenously (through an IV), given about four weeks apart. Between doses and after treatment ends, you will have imaging scans, cystoscopy (a look inside your bladder), and blood tests to see how the cancer is responding. You will then proceed to bladder removal surgery within 12 weeks of starting treatment. After surgery, you will have follow-up visits at 6, 12, and 24 months, which include physical exams, imaging scans, bladder checks, and questionnaires about your quality of life and any long-term effects from the medication.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Netherlands